Lofexidine a centrally acting alpha-2 adrenergic agonist, was launched specifically

for symptomatic relief in patients undergoing opiate withdrawal programmes. In open studies in small groups of methadone dependent patients, lofexidine treatment enabled successful detoxification (defined as remaining drug free for 10 days after the last methadone dose) in greater than 65% of patients.